Audax Medical, Inc. a privately-held medical device company specializing in the development of osteobiologics, has entered into a comprehensive license agreement with Brown University, acquiring exclusive rights to a proprietary osteobiologic nanotechnology.
The biomaterial, Arxis™, is being developed for use in multiple clinical applications for the regeneration of diseased bone, cartilage, and other soft tissues.
An additional research agreement has been completed with the Brown University School of Engineering and Department of Orthopedics to further support clinical development of the technology.
"Our partnership with Brown and the University's world-class scientific team is a significant milestone for Audax Medical," stated Mark A. Johanson, President and Chief Executive Officer. "The addition of this technology to the company's product portfolio greatly expands our growing regenerative osteobiologics and soft tissue platforms."
Under the terms of the agreement, Audax Medical has obtained exclusive license to a platform of intellectual property and technologies co-developed by Thomas Webster, Brown professor of engineering, addressing the treatment of degenerative bone and soft tissues.
"We are very excited to have partnered with such an experienced and accomplished team at Audax Medical," stated Katherine Gordon, Managing Director of the Brown University Technology Ventures Office. "The scientific and commercial expertise from both the Brown and Audax teams are impressive, offering a significant opportunity for both clinical and commercial success."
The Arxis™ biomaterial consists of organic nanomolecules which have the potential to meet an array of clinical needs. The implantable material can incorporate varying growth agents that allow its end characteristics to be customized for multiple clinical and regenerative indications throughout the musculoskeletal system.